Association between rosiglitazone use and decline in renal function in patients with type 2 diabetes mellitus

Journal of Nephrology

Volumn 23, Issue 3, 2010, Pages 350-356

  Feldman, Leonid ^a,b   Shani, Michal ^b,c   Efrati, Shai ^a,b   Beberashvili, Ilia ^a   Baevsky, Tuvia ^c   Weissgarten, Joshua ^a,b   Vinker, Shlomo ^b,c  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c CLALIT HEALTH SERVICES   (Israel)

Author keywords

Albuminuria; Diabetes mellitus; Estimated glomerular filtration rate; Renal function; Rosiglitazone

Indexed keywords

HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE;

ADULT; ALBUMINURIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 77951724488     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world: a growing challenge. N Engl J Med. 2007;356:213-215. (Pubitemid 46143224)
2. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346:1145-1151.
3. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
4. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
5. Nelson RG, Newman JM, Knowler WC, et al. Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia. 1988;31:730-736.
6. Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care. 2004;27:1330-1334. (Pubitemid 38679979)
7. Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. The kidney. 7th ed. Philadelphia, PA: WB Saunders; 2004:1777-1818.
8. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225-232.
9. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157:1413-1418.
10. Parving HH, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int. 1996;49:1778-1782. (Pubitemid 26186611)
11. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
12. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271:275-279.
13. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year followup study. Arch Intern Med. 1996;156:286-289.
14. Lewis EJ, Hunsicker LG, Bain RF, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462. (Pubitemid 23335891)
15. Lindholm LH, Ibsen H, Dahlöf B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:1004-1010.
16. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001;56:265-294. (Pubitemid 33733092)
17. Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471. (Pubitemid 46919772)
18. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189-1195. (Pubitemid 47403105)
19. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006;70:1223-1233.
20. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003;17:7-12. (Pubitemid 36163426)
21. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes. 2005;54:2206-2211. (Pubitemid 40911285)
22. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19:182-187.
23. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147. (Pubitemid 38129105)
24. Tontonoz P, Nagy L, Alvares JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252. (Pubitemid 28180857)
25. Fagerberg B, Edwards S, Halmos T, et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/ gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia. 2005;48:1716-1725. (Pubitemid 41317824)
26. Home P, Pocock S, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet. 2009;373:2125-2135.